Get started

MRNA

Moderna (MRNA) Stock Plummets on Weak Sales OutlookModerna Inc. (NASDAQ: NASDAQ:MRNA ) is facing tough times as its stock dropped over 11% during Thursday’s premarket trading session. The biotech giant, known for its breakthrough COVID-19 vaccine, released a disappointing sales outlook for the upcoming years, sparking a significant sell-off among investors. Weak Sales Outlook and Pipeline Adjustments Moderna (NASDAQ: NASDAQ:MRNA ) has projected sales between $2.5 billion and $3.5 billion for 2025, a far cry from the multi-billion dollar revenues seen during the peak of the COVID-19 pandemic. This forecast falls below analysts’ expectations, who anticipated revenues of $3.27 billion for 2024 and $3.74 billion for 2025. The company’s revenue has been declining since the pandemic boom, with 2023 expected to be the lowest annual revenue since its first COVID-19 vaccine launch in late 2020. Moderna (NASDAQ: NASDAQ:MRNA ) is now betting on its 10 new product launches by 2027 to drive an average annual growth rate of 25% in revenue between 2026 and 2028. However, Moderna CFO James Mock highlighted the uncertainty of the COVID-19 and RSV markets, admitting that these new products may not contribute significant revenue until later years. Moderna’s strategic pivot includes significant cost-cutting measures, with plans to slash $1.1 billion in expenses by 2027. This includes reducing R&D spending from an expected $4.8 billion this year to between $3.6 billion and $3.8 billion by 2027. Despite these reductions, the company is still committed to advancing its pipeline, which includes new mRNA vaccines against RSV, norovirus, and cancer, among others. Challenges Ahead: Competition and Pipeline Delays Moderna’s market position is increasingly challenged by competitors like Pfizer (PFE) and GSK (GSK), who are also pursuing expanded approvals for their RSV vaccines in the same high-risk adult age groups. Moderna’s recent decision to drop its request for fast-track approval of its standalone flu vaccine reflects its strategic realignment towards combination shots that offer protection against multiple viruses, including COVID-19 and influenza. The company's standalone flu shot, mRNA-1010, recently met immune-response targets in clinical trials, but it's still a long way from regulatory approval. Moderna's CEO, Stéphane Bancel, remains optimistic about the company's robust drug development capabilities, boasting that Moderna's rate of success from phase one to phase three trials is “six times higher” than the industry average. Technical Outlook Technically, Moderna's stock price is reflecting the weak fundamentals. The stock is down 10.45% in premarket trading, which adds to the already bearish momentum. On Wednesday, the Relative Strength Index (RSI) for Moderna (NASDAQ: NASDAQ:MRNA ) was 37, indicating a weakened position. The current dip below the $73 mark will likely push the RSI further into oversold territory, raising concerns about heightened selling pressure. The critical technical level to watch is the $60 pivot, a major support zone that aligns with the September 2020 lows. Should Moderna’s stock breach this support, it could trigger a cascade of selling as investors lose confidence, potentially leading to a more severe downturn. This level has historically served as a strong base, and a breakdown could erase gains made over the last four years. What’s Next for Moderna? While Moderna’s long-term prospects hinge on the successful launch of its new mRNA-based therapies, the immediate outlook appears bleak. The company’s efforts to expand into new markets like RSV and flu vaccines are promising, but the revenue impact of these products won’t be felt until at least 2025. Investors should brace for volatility as the company navigates through a post-pandemic market landscape with reduced COVID-19 vaccine sales and increasing competition. For now, Moderna's technical indicators signal caution. The stock's proximity to major support zones and the bearish momentum could prompt further declines if market sentiment does not improve. Investors are advised to keep a close eye on how the company’s strategic decisions unfold and whether Moderna (NASDAQ: NASDAQ:MRNA ) can successfully deliver on its ambitious pipeline goals in the face of growing market challenges.
NASDAQ:MRNAShort
by DEXWireNews
MRNA, bound for exponential growth! MASSIVE RISE in 12 months!MRNA went parabolic during the COVID era reaching as high as 500. Then it went on a cooling down mode coincindingly when the pandemic has started fading. Now a BIG SHIFT has been registered based on its long term data metrics. This is massive because it took the stock 2.5 years to make this happen again. A breakout has been spotted on its long term trend. We got a break in structure confirming that major position takers has started piling up already for that new round of massive growth prospect. Histogram registered it's elusive 'hop' over the line already. First time in ages. The most awaited confirmation is ON. Best seeding season is NOW. This will be an investors' gem. Spotted at 140.0 Interim target at 300.0 Long term: 500. TAYOR.
NASDAQ:MRNALong
by JSAL
2
Moderna Stock Dips More Than 20% Amid Slashed Sales GuidanceModerna Inc. (NASDAQ: NASDAQ:MRNA ) experienced a significant drop in its stock price, plummeting over 20%, following the announcement of reduced full-year sales guidance. The biotech company, renowned for its mRNA technology, reported second-quarter earnings that exceeded Wall Street expectations but highlighted several challenges that led to the downward revision of its revenue forecast. Q2 Performance Overview Moderna ( NASDAQ:MRNA ) reported a narrower-than-expected loss of $3.33 per share, compared to analyst expectations of a $3.39 loss. The company's revenue for the second quarter stood at $241 million, surpassing the anticipated $132 million. However, this figure still represents a 30% year-over-year decline from the $344 million reported in the same period last year. The decrease was primarily driven by a 37% drop in product sales from its Covid-19 vaccine, Spikevax, which brought in $184 million during the quarter. Slashed Full-Year Guidance Despite the better-than-expected quarterly performance, Moderna ( NASDAQ:MRNA ) reduced its 2024 product revenue guidance to a range of $3 billion to $3.5 billion, down from the previous forecast of $4 billion. The company attributed this adjustment to several factors: 1. Lower Sales in Europe: Moderna cited reduced demand for its Covid-19 vaccine in Europe as a major contributor to the lowered guidance. 2. Competitive U.S. Market: The company faces stiff competition in the U.S. market for respiratory vaccines, particularly for its newly approved respiratory syncytial virus (RSV) vaccine, mRESVIA. This vaccine, which targets older adults, entered a market already dominated by Pfizer and GSK. 3. Deferred International Revenue: Moderna indicated the potential for delayed international revenue, pushing some sales into 2025 due to ongoing budget constraints and economic pressures in various countries, including those exacerbated by the war in Ukraine. Strategic Adjustments and Future Outlook In response to these challenges, Moderna ( NASDAQ:MRNA ) has been proactive in reducing operating costs. The company's cost of sales for Q2 was $115 million, down 84% from the same period last year. This reduction includes $14 million in write-downs of unused Covid-19 vaccine doses and $55 million in charges related to scaling back its manufacturing footprint. CEO Stéphane Bancel emphasized the company's commitment to managing costs and optimizing its product pipeline. He noted, “We’ve been having quite intense discussions with governments across Europe to secure Covid vaccine supply contracts, but tight budgets and existing agreements with other suppliers have limited our opportunities.” Despite the current setbacks, Moderna remains optimistic about its future. The company expects to return to sales growth in 2025 and aims to break even by 2026. Key to this strategy is the launch of new products and continued innovation within its pipeline. Moderna currently has 45 products in development, with five in late-stage trials. These include a combination shot targeting Covid-19 and the flu, which could receive approval as early as 2025, a stand-alone flu vaccine, and a personalized cancer vaccine in collaboration with Merck. Investor Sentiment and Market Response While Moderna's shares have risen nearly 20% this year due to increasing confidence in its pipeline and mRNA platform, the recent guidance cut has significantly impacted investor sentiment. Modern stock ( NASDAQ:MRNA ) has dropped from its consolidation zone and has formed a significant downward gap. In trading, gapping happens when the price of a security jumps to a new price that's not right next to the previous price, creating a gap on the price chart. This can occur during a trading day or when the markets are closed. Gaps can happen unexpectedly when the perceived value of an investment changes due to fundamental or technical factors, such as earnings. In this case, NASDAQ:MRNA is in a downward gap, also known as a negative gap, which occurs when the opening price of a stock on the second day is lower than the closing price on the first day. Conclusion Moderna's recent financial performance highlights the volatility and competitive nature of the biotech industry, particularly in the evolving landscape of respiratory vaccines. While the company faces immediate challenges, its strategic cost management and robust pipeline position it for potential recovery and growth in the coming years.
NASDAQ:MRNA
by DEXWireNews
Bullish Anti-Shark Harmonic on MRNAI've spotted some bullish harmonic patterns on Moderna (MRNA) that are showing strong potential! 📈 There's one fully formed pattern and another one waiting to complete. 📊 The Relative Volume (RVOL) average is backing the strong support levels, suggesting that MRNA might be bottoming out around this area. 🌟 📉 Chart Analysis: 1️⃣ The current pattern shows a potential reversal from the recent downtrend, with significant support around the $104.91 level. 2️⃣ The RVOL indicates increased buying interest, which further supports the likelihood of a bullish move. 📈 🎯 Trade Setup: Entry Point: Look for confirmations around the support level. Target 1: $136 💰 Stop Loss: $104.91 🚨 📝 Why I'm Interested: The combination of harmonic patterns and strong RVOL support makes this setup particularly compelling. Harmonics often signal high probability reversals, and the volume support adds another layer of confidence. 📊📉 📅 Timeframe: I'm looking at this setup on a 3H chart, which means it could take a couple of days to fully play out. ⏳ 🔔 Stay Updated: Make sure to keep an eye on the price action and adjust your strategy as needed. Happy trading! 🎯 #MRNA #Harmonics #RVOL #Trading #StockMarket #TechnicalAnalysis #TradeTalkFarsi 📈🚀
NASDAQ:MRNALong
by TradeTalkFarsi
MRNA Taking Profit, Watching for a add LONG after a pullback.MRNA has been on fire since the earnings beat 4 weeks ago and has added 60% to its market cap in the past three months. It compares well with NVAX which as a prior penny stock has more volatility and upside potential. In general vaccine stocks are performing well as COVID RSV and influenza vaccines are active in research are Viral Hepatitis vaccine enhancements and the drive for an HIV vaccine. MRNA is strong and perhaps becoming overbought. The mass index indicator has topped and maybe falling to the trigger line. I will take a one- third partial off my position here and wait for a pullback with reversal to add back into the position at a lower price. The tandem of MRNA and NVAX has been very profitable for me. Careful in trade management will help me keep it that way.
NASDAQ:MRNALong
by AwesomeAvani
NVAX pushed to bottom of its channel LONGNVAX powered off its earnings and a news catalyst and is overdue now for a correction. While in an ascending channel NVAX is now at the bottom of the channel perhaps due to the general market moves this week. From here it can move up in the channel or breakdown and fall into a significant correction from the uptrend since May 10th. I am bullish on NVAX and have a prior perspective of an insider. I have realized profit six figures from my call options for January 2025 and have a large number remaining in the trade. At this juncture, I will watch for NVAX to move up in the channel and take a trade of shares and some call options for 15.00 expiring in June 2025 to take advantage of long term capital gains on the options. The FDA is currently reviewing some COVID vaccine data which is particularly relevant to NVAX. The volume profile has a shelf at 14.25 which will be my stop loss on the shares. The options will have a 20% stop loss. Considering the level from which NVAX has fallen over a period of some period there is great potential in my opinion.
NASDAQ:NVAXLong
by AwesomeAvani
2
$MRNA. Ready for a boost? Today the markets took a toll but caught a bounce by the end of market close. A few sectors did hold up well structure wise. Those sectors were AMEX:XLV and $XLC. With this in mind, a flow order came in today for $MRNA. NASDAQ:MRNA trades within the AMEX:XLV sector (Healthcare) so automatically this caught my eye. This order is a $155 call expiring 6/7. With the healthcare holding up and this order is bullish on mrna it seems like we will long this ticker into 6/7. Price Action & Zones: We are in a trending parallel right now (buyers getting in control). Within the parallel it seems we took out the buyers and the sellers and then price came back into the range. Expected range is $160.84 for the upside and $134.80 for the downside, liquidity will lay at these levels. Watering hole from $152.97 - $154.01. Entry/Add/Target/Exit: Entry is on 50-60% discount or a gap up and hold for a while, maybe a chop and a C leg to follow. The add time is market close (if we enter market open). Target is when we are up 50-70% of our contracts value (hold a runner). Exit is if we lose upwards momentum and tank past 60% discount.
NASDAQ:MRNALong
by OakFDom
Moderna Breaks Out 12.68% For The First Time In A YearModerna ( NASDAQ:MRNA ) stock broke out for the first time in a year after beating Wall Street's first-quarter expectations as its second potential approval looms. The company hopes to win Food and Drug Administration approval for its RSV vaccine, which causes cold-like symptoms in most people but can be serious or deadly in babies and older adults. The FDA is due to make its decision on Moderna's shot in less than two weeks. Moderna ( NASDAQ:MRNA ) hopes to launch its vaccine for older adults this fall. If approved, this would be Moderna's second commercial product behind its Covid vaccine. Moderna's Covid vaccine sales plummeted nearly 91% to $167 million during the first quarter, but handily beat analysts' forecast for $93 million. The European Union plans to buy up to 36 million doses of its Covid vaccine each year for at least four years. The company expects "higher vaccination uptake" in the U.S. if its updated Covid vaccine is available in time with the seasonal flu shot. From a financial standpoint, Moderna ( NASDAQ:MRNA ) is retaining its outlook for the year. The company expects to notch $4 billion in sales of its respiratory vaccines. That will be weighted to the back half of the year with less than $300 million in sales projected for the first half of 2024. Moderna ( NASDAQ:MRNA ) stock analysts project $4.19 billion in full-year revenue, including $4.06 billion in sales from the company's products. The RSV vaccine could be a big moneymaker for Moderna ( NASDAQ:MRNA ). Pfizer and GSK launched their RSV shots for older adults last year, with Abrysvo and Arexvy generating $145 million and $228 million in sales respectively. Moderna stock analysts already expect some sales of Moderna's product — $10 million in the June quarter, according to FactSet. Moderna is ( NASDAQ:MRNA ) also planning to work with U.S. regulators on the timing of its next Covid vaccine. Officials will choose the next variant to target in booster shots on May 16, then it will be off to the races, so to speak, to run testing for Moderna's updated shot. Moderna's goal is to launch the Covid booster shot in timing with the fall flu vaccine campaign.
NASDAQ:MRNALong
by DEXWireNews
✏️ Weekly Report: Volatility makes Cash the King againGENERAL COMMENTS Today, the Federal Reserve maintained its interest rates unchanged, highlighting the ongoing challenges in curbing inflation. Initially, this announcement propelled the markets upwards, but a sharp downturn occurred in the final hour, leading to a decline as the day concluded. The erratic market behavior demonstrated today makes it increasingly challenging to maintain positions in momentum stocks, and the majority of this quarter's earnings reports have been underwhelming. This situation underscores the strategy that cash remains paramount, complemented by selective, quick trading opportunities, as depicted in the following charts. I will begin tonight's chart analysis with the Nasdaq-100 (QQQ). NASDAQ:QQQ The Qs are forming a bearish formation. What is worrying is that this is below the 50D Simple Moving average. As trading is a probabilities game, we can conclude that this leads to probabilities being lower that we continue to the downside. However, the direction of the general market indexes are very well influenced by the fundmental story of the economy health. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:SMTC SMTC is up $4 from the $33 Buy Point (alerted in previous versions of this idea - go and check. Believe and Follow). This peaked yesterday with about +20% profit since the alert last week. Of course the way I manage this is never to let this to turn into a loss. My general go to tool is to take half here. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:KLAC KLAC fell back to $687 after missing earnings. This of course stopped me out - but at no loss, since I move stopped up to break-even. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:SMCI The stock missed its earnings and suffered a severe reaction of a gap down and drop -20% on the intraday. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:NVDA NVDA slashed below the 50D SMA and this stopped me out. Waiting and watching this TML during its base building period. –––––––––––––––––––––––––––––––––––––––––––––––––––– NYSE:GS Up $7 from the $419 buy point with stop raised to $416 just in case. –––––––––––––––––––––––––––––––––––––––––––––––––––– NYSE:CRM CRM is prone to go lower if the market continues falling. A break below $266.50 is great place to short. –––––––––––––––––––––––––––––––––––––––––––––––––––– NYSE:LLY Gapped up on good earnings. The next technical buy point is $801 accommodated with heavy volume. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:MRNA Earnings are due out tomorrow. If earnings are good then zooming through the $116 on good volume is a great technical buy point
NASDAQ:QQQ
by SimplerSignals
XBI the ETF for Biotechnology LONGBiotechnology is expected to be a hot subsector this year as healthcare recovered further from the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend with XBI pivoting to bullish back in early November. I add long positions when I see a dip on the 3-4hr chart. My targets are the fib retracement expectation at 116 confluent with the first upper VWAP band line and then the 135-138 zone underneath the second upper line shown in thin red on the chart. This ETF smooths out the volatility characteristic of some of the smaller biotechnology firms making it safer albeit with lesser rewards expectations. Positions in NVAX and MRNA are having a good start to the week and will reflect in a small way in this ETF which has broad constituent stocks within its portfolio.
AMEX:XBILong
by AwesomeAvani
1
Moderna's Vaccine Spark Hope in Head and Neck Cancer TreatmentIn a significant breakthrough for cancer treatment, Moderna's ( NASDAQ:MRNA ) individualized cancer vaccine, developed in collaboration with Merck, has shown remarkable promise in an early-stage trial targeting head and neck cancer. The encouraging results have ignited a surge in Moderna's stock price and injected fresh optimism into the field of oncology research. The vaccine, mRNA-4157, aims to train the immune system to identify and combat specific mutations present in cancer cells, representing a pioneering approach in personalized cancer therapy. Following its success in treating melanoma, the vaccine has now demonstrated positive responses in patients with head and neck squamous cell carcinoma, a challenging form of cancer. Data presented at the American Association for Cancer Research Annual Meeting showcased the vaccine's efficacy when administered in combination with Merck's Keytruda. The study, involving 22 patients, revealed promising clinical responses, including instances of complete remission. Notably, the combination therapy not only triggered robust immune responses but also exhibited favorable safety profiles, marking a significant milestone in cancer immunotherapy. Jefferies analyst Michael Yee lauded the results, highlighting the potential of Moderna's therapy platform to transcend melanoma and extend its benefits to other cancer types. The data underscore the transformative potential of mRNA-based vaccines in revolutionizing cancer treatment paradigms and offering new hope to patients grappling with advanced malignancies. The positive outcome has bolstered investor confidence in Moderna ( NASDAQ:MRNA ), propelling its shares to a three-month high. This uptrend reflects renewed enthusiasm for the biotech firm's diverse pipeline, which includes groundbreaking vaccines targeting respiratory syncytial virus and other infectious diseases, alongside innovative cancer therapies. Looking ahead, Moderna's collaboration with Merck signals a concerted effort to advance the development of cancer immunotherapies. The initiation of a Phase 3 trial targeting lung cancer underscores the commitment to translating promising preclinical data into clinically meaningful outcomes, to deliver transformative therapies to patients in need. As Moderna ( NASDAQ:MRNA ) continues to pioneer the frontier of mRNA-based therapeutics, the recent success of its cancer vaccine heralds a new era in precision medicine. With further advancements and clinical validations, this innovative approach holds the potential to reshape the landscape of cancer treatment and offer renewed hope for patients battling this devastating disease.
NASDAQ:MRNALong
by DEXWireNews
$MRNA Bearish to Bullish Reversal NASDAQ:MRNA Bearish to Bullish Reversal A "Bearish to Bullish Reversal" in technical analysis for NASDAQ:MRNA suggests a shift in the stock's price movement pattern from a downward trend (bearish) to an upward trend (bullish). This reversal typically occurs after a period of decline, indicating that the stock may be transitioning from a bearish phase to a bullish phase. It could signify a potential turning point in market sentiment, with investors becoming more optimistic about the stock's future prospects. Traders often look for confirmation signals to validate this reversal, such as increased trading volume or positive fundamental developments in the company.
NASDAQ:MRNALong
by AlgoTradeAlert
Moderna Surge as it Dives into Promising Cancer Vaccine TrialsModerna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be attributed to several key factors that are igniting investor enthusiasm and confidence in the company's future prospects. One of the primary catalysts driving Moderna's stock rally is the initiation of a mid-stage clinical trial for its experimental cancer vaccine targeting cutaneous squamous cell carcinoma, a prevalent form of skin cancer. This groundbreaking trial, conducted in collaboration with Merck, underscores Moderna's commitment to pioneering innovative solutions in oncology. In addition to advancements in oncology, Moderna ( NASDAQ:MRNA ) continues to make significant strides in addressing infectious diseases, oncology, and rare diseases. Despite the challenges posed by the endemic market, Moderna ( NASDAQ:MRNA ) reported notable pipeline advancements in its fourth-quarter results. The company anticipates initial regulatory approvals for its RSV vaccine (mRNA-1345) starting in the first half of 2024, further bolstering its position in the market. Moreover, Moderna ( NASDAQ:MRNA ) remains optimistic about its COVID-19 franchise, projecting profitability in anticipated sales scenarios for 2024 and beyond. With approximately $4 billion in product sales expected in 2024, primarily driven by COVID-19 vaccine sales and the launch of its RSV vaccine, Moderna is poised for robust growth in the coming years. Technical Analysis Shares of Moderna ( NASDAQ:MRNA ) is exhibiting a bullish Flag pattern indicating the NASDAQ:MRNA has reacted to the Promising Cancer Vaccine Trials news. With a moderate Relative Strength Index (RSI) of 68.74 NASDAQ:MRNA shares is gaining momentum. Looking ahead, Moderna's pipeline update revealed a promising outlook, with 45 therapeutic and vaccine programs, nine of which are in late-stage development. Notably, the Phase 3 trial of its combination vaccine against seasonal flu and COVID-19 has been fully enrolled, with data expected in 2024. These developments underscore Moderna's commitment to innovation and its potential to deliver groundbreaking therapies to address critical unmet medical needs. In conclusion, Moderna's recent stock rally reflects growing optimism and confidence in the company's innovative pipeline, particularly in the areas of oncology and infectious diseases. With promising clinical trials underway and a robust portfolio of vaccine candidates, Moderna is well-positioned to capitalize on emerging market opportunities and drive long-term value for investors. As the company continues to make strides in pioneering mRNA technology, investors can expect Moderna to remain at the forefront of medical innovation, potentially revolutionizing the treatment landscape for various diseases, including cancer.
NASDAQ:MRNALong
by DEXWireNews
NVAX rises impending an earnings report LONGToday NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings is coming this upcoming week. This week NVAX news release showed it had settled a years long litigation over a failed COVID. In the face of earnings around the corner, was this news release a coincidence or instead a case of excellent executive and legal timing? I will skip the conspiracy discussion. On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock that has been stuck in deeply undervalued territory for a significant time period is remarkable. I have bought far out of the money call options into 2025 and 2026 some only this past month. Those from this month are now up over 250% with 11 and 23 months to go to expiration. I see NVAX as a risky penny medical stock with a high reward potential relative to the risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out the competition when there is an opportunity and do not worry about the government crying monopoly when life-saving and life-extending medical products are involved. Time will tell. I expect insane profits.
NASDAQ:NVAX
by AwesomeAvani
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area of the volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing position here and again the next time I see a dip on the 15-30-minute chart. I look forward to take a piece out of the position after the next earnings report in about 75 days. I have an alert for relative volume when the running mean is exceeded on the 30 minute chart which notify me to take a look at the chart. This is illustrated on this longer time frame chart about the days around earnings but occurs from time to time from other events. As an aside, if NVAX gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be the leading candidate to do a takeover, friendly or otherwise.
NASDAQ:MRNALong
by AwesomeAvani
NVAX- a medical penny stock Buy Weakness LONGNVAX on a 120 minute chart demonstrates a trend down in the past month after a period of consolidation producing the POC line on the volume profile. The MACD shows some bullish divergence. The volume profile has high volume nodes at 4.0 and 5.0 separated by a relative volume void. NVAX fell quickly through that void. It can just as easily rise through it. See the linked article on NVA from TipRanks. Options volume and pricing analysis is that bets are looking at5.0 diligently. Fundamentally, NVAX has been range limited by its focus on COVID but it does have other projects in its pipeline admittedly on various timelines with varying probabilities of capitalizing on them depending on clinical trials FDA approvals and so on. On the imbedded relative strength table as compared with SPY and peers in the pharmaceutical, biotechnology, medical device and healthcare spaces NVAX compares favorably with MRNA its closest peer but is weak compared with most of the others I have selected especially with LLY, which is high-flying from its anti-obesity drug breakout. Device companies Stryker and Intuitive Surgical are quite strong as well. United Healthcare is dominant in the insurance subsector and strong overall. One often effective strategy is to buy when an instrument is oversold and undervalued at a discount. I will buy NVAX here no matter that I have insider connections with one of those medical device companies and a few not on the list. Sentiment only goes so far. I found the article compelling and so Novavax long I go. On a trading site left unsaid my screenname is "Bottom Feeding Grinder". I have an appetite for NVAX found at the bottom right now. This is a reversal/reversion to the mean long trade. It is not without risk. As a penny stock with high volumes, low cost of entry and perhaps low floats, volatility is underscored and exaggerated if a volume inflow gets underway That said, a short squeeze is within the spectrum of possibilities. Enough said for now.
NASDAQ:NVAXLong
by AwesomeAvani
Novavax- NVAX- Medical Technology Vaccine Focused LONGNVAX on the 15 minute chart has been compressing price action volatility into a symmetrical triangle. It in now in a breakout of the triangle and in the process when from undervalued on Monday to the upper trendline and then down to the support trendline and then up again. It passed through the volume profile and its high volume area. In short, it has bullish momentum capped off with a breakout from the high volume area into a bullflag to rest the weekend. I am in this stock going and now is an opportunity to add to the position. If a trader wants to know what I consider to be targets upside, let me know. Medical technology is expected to be among the hottest of subsectors for 2024. NVAX has been beaten down. I believe it has significant upside for the long term. in the short term, earnings are expected on February 28th so this is a trade to consider on that run up. Call options for March 2 or March 16 can be considered.
NASDAQ:NVAX
by AwesomeAvani